CARA Therapeutics, Inc.

CARA Therapeutics, Inc. is currently overvalued with negative valuation ratios and a risky valuation grade, despite a strong year-to-date stock performance of 111%, but its long-term outlook is concerning with a 3-year return of -89.45%.

CARA Therapeutics, Inc. has shifted to a risky valuation grade due to negative financial metrics indicating overvaluation, including a P/E ratio of -6.2350 and a troubling ROCE of -875.16%, despite a strong one-year stock return of 154.51%.

As of June 11, 2025, CARA Therapeutics, Inc. shows a strong bullish trend supported by positive indicators like the weekly MACD and daily moving averages, despite some caution from the Dow Theory's mildly bearish signal.

As of March 2022, CARA Therapeutics, Inc.'s management team includes Dr. Derek Chalmers as President and CEO, with Mr. Martin Vogelbaum as Lead Independent Director and several Independent Directors including Susan Shiff, Mr. Harrison Bains, Dr. Jeffrey Ives, and Mr. Christopher Posner.

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for pain and pruritus. As of March 2025, it has a market cap of $234.68 million, with net sales of $3 million and a net loss of $5 million.

As of Jun 18, CARA Therapeutics, Inc. has a market capitalization of 234.68 million, with net sales of 7.58 million and a net profit of -45.09 million over the last four quarters. The company reported shareholder's funds of -4.59 million and total assets of 43.83 million as of Dec 24.